Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 2 de 2
1.
J Control Release ; 78(1-3): 235-47, 2002 Jan 17.
Article En | MEDLINE | ID: mdl-11772464

Cardiovascular disease processes such as atherosclerosis, restenosis, and inflammation are typically localized to discrete regions of the vasculature, affording great opportunity for targeted pharmacological treatment. Liposomes are potentially advantageous targeted drug carriers for such intravascular applications. To facilitate their use as drug delivery vehicles, we have considered three components of liposome design: (i) identification of candidate cell surface receptors for targeting; (ii) identification of ligands that maintain binding specificity and affinity; and (iii) prevention of rapid nonspecific clearance of liposomes into the reticuloendothelial organs. In this report, we describe our work in developing liposomal surface modifications that address both targeting and clearance. An arginine-glycine-aspartic acid (RGD) containing peptide was used as a model ligand to target liposomes to the integrin GPIIb-IIIa on activated platelets. Additionally, oligodextran surfactants incorporated into liposomes provided insight into the effect of vesicle perturbations on liposome clearance, and the importance of molecular geometry in designing oligosaccharide surface modifications. Together these studies demonstrate the feasibility of using peptides to guide liposomes to desired receptors, and illustrate the influence of vesicle stability on liposome interactions in vivo. Furthermore, they underscore the importance of simultaneously considering both targeting specificity and vesicle longevity in the design of effective targeted drug delivery systems.


Cardiovascular Diseases/drug therapy , Drug Delivery Systems , Liposomes/administration & dosage , Oligopeptides/administration & dosage , Oligosaccharides/administration & dosage , Animals , Dextrans/administration & dosage , Female , Liposomes/chemistry , Mice , Mice, Inbred BALB C , Platelet Glycoprotein GPIIb-IIIa Complex/administration & dosage
2.
J Colloid Interface Sci ; 252(1): 57-65, 2002 Aug 01.
Article En | MEDLINE | ID: mdl-16290762

Novel glycolipids, which contain 2 and 15 oligomaltose units and a phosphatidylethanolamine, were synthesized and characterized by FTIR and (1)H-NMR spectroscopies. The well-defined linear structure of the glycolipids was assured by an end-point conjugation strategy using selective oxidation of the reducing end groups of maltose oligosaccharides, followed by aminolysis with distearoylphosphatidylethanolamine. The intermediate acids react selectively with amines to form amide linkages, catalyzed by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and N-hydroxysuccinimide. Conformations of the glycolipids at the air-water interface were proposed based on the film balance measurements. The unique conformations of glycolipids at interfaces may offer advantages over traditional PEO-derived lipids in regard to their applications for sterically stabilizing liposomes. The glycolipids demonstrated the ability for sterically stabilizing liposome dispersions, as determined by turbidity measurements.


Glycolipids/chemical synthesis , Liposomes/chemical synthesis , Maltose/analogs & derivatives , Oligosaccharides/chemistry , Phosphatidylethanolamines/chemistry , Catalysis , Ethyldimethylaminopropyl Carbodiimide/chemistry , Magnetic Resonance Spectroscopy , Membrane Fluidity , Nephelometry and Turbidimetry , Spectroscopy, Fourier Transform Infrared , Succinimides/chemistry , Surface Properties
...